In terms of your comment about a strategy for end-of-day vaccinations, given the cohort we're currently working through of everyone 50 years and above, and running our second dose programme, at this point of time we really shouldn't have difficulty in using the supplies that we've got. We're largely directing the Pfizer jabs at present for the second dose programme, because that's the stage that we're still working through from the earliest doses before AstraZeneca came on board and was delivered more widely. But in terms of our use of AstraZeneca, it's not the case that we expect to see large amounts of wastage, and that's one of the good things, I think, we've been doing from an early point; we've been publishing our figures on waste, which is showing that the programme in Wales is not just going through at a very fast pace, but it's highly efficient, with very, very low wastage rates. That, again, is to the credit of the programme and the deliberate time we took at the outset to get everything right in the way we set up the programme. As we get towards the end of the cohort, and as we're looking to roll out and go into the next age range, we may face a time where there is a more realistic prospect of needing an end-of-day plan in reality. We've already written out and given guidance to the service on doing that, so we certainly don't want to see vaccines wasted. We've had a range of conversations with emergency services workers and others—but I don't think that's going to be a present problem for us now, given the scale and the numbers of people that we have to do and the cohorts that are still available.

I've got to work too with officials on when we'll be moving into the under-50s age group. You'll recall that we were at the point of practical completion when we had essentially delivered 80 per cent of groups 1 to 4, with others then having had invites to their appointments. We were able then to start inviting as a matter of course people in the next ages, for the next part of the roll-out. So, we need to look again and confirm as soon as possible the approach we'll take for the next stage of the vaccination programme. And we do look at the speed across Wales; it's a conversation we have at the vaccination board each week. So, that is a conversation, and it's an open conversation, in a positively competitive way. Each part of Wales wants to see how quickly it can make progress. In every part of Wales, I think the vaccination programme is in a good place, and it's a good problem to have about how fast can we go, rather than having people who are lagging and outliers. And again, when you compare us to other European countries, we're doing extraordinarily well.

I want to reiterate that people should get a test and seek help. TTP includes the contact tracers, but also the supportive part of it, the 'protect' element of it. There are regular calls to people who are isolating—to make sure they are isolating, but also, and primarily, to make sure that there's a well-being check, there's an opportunity to talk to someone, to make sure they are aware of where they can get help and support practically to manage with isolation. Self-isolating is still really important in protecting people around you. It's one of the most effective things we can do to halt the spread of the virus, and that will be even more important as we go through each stage of unlocking more measures.

And finally, on blood clots, it is a matter of fact that, at present, the risk of blood clots is higher, in fact, from the evidence as we understand it, in the unvaccinated population, compared to people who have had the AstraZeneca vaccine. The figures show it's actually slightly lower. And there is no evidence linking blood clots to the AstraZeneca vaccine itself. I appreciate that other countries want to work that through. But I am definitely confident in the evidence we have across the UK, having delivered more than 12 million doses of AstraZeneca. The numbers of people who reported having a blood clot without there being any evidence that's come from the vaccine is lower than in the rest of the population. So, it's a concern. We hope people will look at the evidence, and act on the evidence, to protect themselves and encourage others to get that protection. Because having COVID means you're much more likely to get a blood clot and much more likely to suffer serious harm.